How it works Clinical evidence Comparison with other GLP-1s Market outlook References Further reading Orforglipron, the first promising oral small-molecule GLP-1, is demonstrating weight-loss and metabolic results that could reshape obesity treatment and challenge injectable standards
Clinical trial data including the FLOW trial (NEJM, 2024) and earlier cardiovascular outcome trials such as LEADER and SUSTAIN-6 suggest these agents may offer renoprotective benefits in people with type 2 diabetes and CKD , including reductions in albuminuria and slowing of disease progression
Insulin syringe vs tuberculin syringe Both insulin syringes and tuberculin syringes are small-volume injection devices
Many insurance plans require BMI documentation, medical records, and weight-related diagnoses before approving coverage
4 Wegovy pill offers a magnitude of weight loss that no other oral GLP-1 obesity candidate has been able to duplicate in phase 3 trials, boasting an average weight loss of about 17% (16.6%), when used along with a reduced calorie diet and exercise and if all patients stayed on treatment, compared to about 3% (2.7%) for placebo
Patel A, Torre B, Young B, et al
